Press Releases

Endeavor BioMedicines white Icon
2024

Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer

SAN DIEGO – April 16, 2024 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life...

Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D., as President and Vishaal Turakhia as Chief Financial Officer

SAN DIEGO – March 14, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer (CFO). Both Dr. Kariuki and...

Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis

ENV-101 has potential to be the best-in-class treatment for idiopathic pulmonary fibrosis (IPF) Endeavor expects to initiate Phase 2b study of ENV-101 for the treatment of IPF and progressive fibrosing-interstitial lung disease (PF-ILD) in 2024 SAN DIEGO – January 24, 2024 – Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the...

2023

Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D., to Board of Directors

SAN DIEGO – December 19, 2023 – Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, announced that the company has appointed Enoch Kariuki, Pharm.D. to the Endeavor BioMedicines Board of Directors. Dr. Kariuki is an established life sciences executive with extensive strategic, operational, and financial experience. “Dr....

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-HER3 ADC to be developed for patients with HER3-expressing tumors Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from Endeavor BioMedicines Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from Endeavor BioMedicines San...

2022
2021

Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer

Dr. Srikanth Pendyala appointed Chief Medical Officer, bringing over 20 years of expertise in clinical research and translational sciences as company broadens its precision medicines pipeline Phase 2 clinical trial to assess safety and efficacy of taladegib, a Hedgehog pathway inhibitor, as a monotherapy in patients with IPF SAN DIEGO – September...

Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease

Product candidate taladegib inhibits chronic Hedgehog signaling pathway, an underlying mechanism behind Idiopathic Pulmonary Fibrosis (IPF) Two Phase 2 clinical studies investigating taladegib’s potential to slow or reverse IPF disease progression expected to initiate in 2021 SAN DIEGO – January 7, 2021 – Endeavor BioMedicines, a biotechnology company developing new treatments targeting...